Background and purpose: Natural and synthetic cannabinoids (CBs) induce deleterious or beneficial actions on neuronal survival. The Fas-associated protein with death domain (FADD) promotes apoptosis, and its phosphorylated form (p-FADD) mediates non-apoptotic actions. The regulation of Fas/FADD, mitochondrial apoptotic proteins and other pathways by CB receptors was investigated in the mouse brain. Experimental approach: Wild-type, CB1 and CB2 receptor knock-out (KO) mice were used to assess differences in receptor genotypes. CD1 mice were used to evaluate the effects of CB drugs on canonical apoptotic pathways and associated signalling systems. Target proteins were quantified by Western blot analysis. Key results: In brain regions of CB1 receptor KO mice, Fas/FADD was reduced, but p-Ser191 FADD and the p-FADD/FADD ratio were increased. In CB2 receptor KO mice, Fas/FADD was increased, but the p-FADD/FADD ratio was not modified. In mutant mice, cleavage of poly(ADP-ribose)-polymerase (PARP) did not indicate alterations in brain cell death. In CD1 mice, acute WIN55212-2 (CB1 receptor agonist), but not JWH133 (CB2 receptor agonist), inversely modulated brain FADD and p-FADD. Chronic WIN55212-2 induced FADD down-regulation and p-FADD up-regulation. Acute and chronic WIN55212-2 did not alter mitochondrial proteins or PARP cleavage. Acute, but not chronic, WIN55212-2 stimulated activation of anti-apoptotic (ERK, Akt) and pro-apoptotic (JNK, p38 kinase) pathways. Conclusions and implications: CB1 receptors appear to exert a modest tonic activation of Fas/FADD complexes in brain. However, chronic CB1 receptor stimulation decreased pro-apoptotic FADD and increased non-apoptotic p-FADD. The multifunctional protein FADD could participate in the mechanisms of neuroprotection induced by CBs.
Introduction
Apoptosis (programmed cell death) is an indispensable process for the development of any organism and tissue function, including the normal and diseased brain (Lossi and Merighi, 2003) . Programmed cell death is primarily mediated by the extrinsic or death receptor pathway (AlgecirasSchimnich et al., 2002) , and the intrinsic or mitochondrial pathway (Galluzzi et al., 2009) , which converge to activate common executioner caspases (caspase-3/7) with the final cleavage of downstream targets that include DNA repair enzymes (Kumar, 2007) . The self-associated complex formed by Fas receptor with its adaptor Fas-associated protein with death domain (FADD) has a central role in promoting apoptosis (Chinnaiyan et al., 1995; Scott et al., 2009 ). In contrast, phosphorylated FADD (p-FADD; phosphorylated on Ser191 in mouse; phosphorylated on Ser194 in human; Zhang et al., 2004) mediates non-apoptotic actions such as cell growth and differentiation (Alappat et al., 2005) . Recently, the multifunctional Fas/FADD complex and its associated signalling pathways [mitogen-activated protein kinases (MAPK), Akt or protein kinase B, phosphoprotein enriched in astrocytes of 15 kDa (PEA-15)] have also been associated with the induction of non-apoptotic signals (neuroadaptations) in the CNS RamosMiguel et al., 2009; 2010) .
Natural and synthetic cannabinoids mediate their effects through the activation of at least two forms of G i/o proteincoupled receptors, the CB1 and CB2 receptors (nomenclature follows Alexander et al., 2009) . The CNS expression of CB1 (mainly in neurones) and CB2 (glial and neuronal cells) receptors is well documented (Herkenham et al., 1991; Gong et al., 2006) . Among the many effects induced by cannabinoids (Pertwee, 1997; Valverde et al., 2005) , their beneficial or deleterious actions on neuronal survival remain a controversial topic (Guzmán et al., 2002) . Although cannabinoids can induce pro-apoptotic activity in different cellular models (Maccarrone and Finazzi-Agró, 2003) , recent evidence demonstrates that these compounds, acting through CB1 receptors (Aguado et al., 2007) or CB2 (Viscomi et al., 2009 ) and associated signalling pathways [anti-apoptotic MAPK-extracellular signal-regulated kinase (ERK) and phosphoinositide-3 kinase (PI3K)/Akt], can also protect neurones from death (GalveRoperh et al., 2008) .
The predominant CB1 receptor is one of the most highly expressed G-protein-coupled receptor in the CNS, which is mainly located on GABA-ergic axon terminals where it regulates GABA release (Katona et al., 1999) . CB1 receptors also display a high level of constitutive activity (Gifford and Ashby, 1996) and thus can exert a tonic control (i.e. ligandindependent activity) on its endocytic cycle (Leterrier et al., 2004) , as well as on the function of other receptors (Canals and Milligan, 2008) . This contrasts with the brain CB2 receptor whose pharmacological activation has been questioned in conscious rats (Chin et al., 2008) , and therefore the presence of any receptor constitutive activity is uncertain. Recently, the pro-apoptotic Fas/FADD complex was shown to be under the tonic control of d-opioid receptors (García-Fuster et al., 2007b) , an inhibitory receptor with a high level of ligand-independent activity (Costa and Herz, 1989) . Similarly, the remarkable constitutive activity of the CB 1 receptor could be involved in the tonic control of apoptotic cascades and in the actions of endocannabinoids on neuronal death or survival.
Against this background, the aims of the present study were to: (i) determine the influence of genetic deletion of CB1 or CB2 receptor on the basal expression of Fas, FADD and p-Ser191 FADD in mouse brain regions; (ii) assess the effects of WIN55212-2 (CB1 receptor agonist) and JWH133 (CB2 receptor agonist) on FADD, p-Ser191 FADD and other components of the canonical apoptotic pathways; and (iii) investigate the modulation by WIN55212-2 of classic (MAPKs) and new (PEA-15 and Akt kinase) pathways mediating apoptotic or survival actions in the brain. A preliminary account of this work has been given at the 20th ECNP Congress (Álvaro-Bartolomé et al., 2008) .
Methods

Animals and genotyping
All animal care and experimental procedures were conducted according to standard ethical guidelines (European Communities Council Directive 86/609/EEC) and approved by the Local Bioethical Committees. Adult male CB1 (n = 9) or CB2 (n = 13) receptor-deficient [knock-out (KO)] mice and the corresponding wild-type (WT) littermate controls (n = 21) were used (23-28 g) for the assessment of basal neurochemical differences between genotypes. Male Swiss albino CD1 mice (n = 96; 30-35 g; Charles River, Barcelona, Spain) were used for cannabinoid treatments. CB1 and CB2 receptor KO mice were originally generated by homologous recombination as described (Ledent et al., 1999; Buckley et al., 2000) . To homogenize the genetic background, first-generation CB1 receptor heterozygote mice were bred for 30 generations on a CD1 background, with selection for the mutant CB1 receptor gene at each generation. CB2 receptor KO mice (Buckley et al., 2000) with C57BL/6J background were backcrossed with CD1 mice for six generations to obtain CB2 receptor KO mice on the CD1 background. Heterozygote-heterozygote mating ofcante, Spain). The animals were housed under standard conditions (21°C; 12:12 h light/dark cycle), and handled for several days before the experiments to reduce stress.
Treatments with cannabinoid drugs CD1 mice were acutely treated with WIN55212-2 (0.5, 1 or 8 mg·kg -1 , i.p., 1 h), a mixed CB1/CB2 receptor full agonist. To assess the specificity of the CB receptor involved, other mice received rimonabant (SR141716; 10 mg·kg -1 , i.p.), a selective CB1 receptor antagonist/inverse agonist (Pertwee, 2005) , alone (100 min) or 40 min before WIN55212-2 (1 mg·kg -1 ). Other groups of mice were acutely treated with JWH133 (1 and 3 mg·kg -1 , i.p., 1 h), a selective CB2 receptor full agonist (Huffman, 2005) . Control mice received drug vehicle (Cremophor : ethanol : water, 1:1:18 proportion or DMSO : Tween 80 : water, 1:1:8 proportion; 2 mL·kg -1 , i.p., 1 h). The doses of WIN55,212-2, rimonabant and JWH133 were chosen from earlier studies (Moranta et al., 2007 ; see also Barna et al., 2009) .
For the chronic treatment with WIN55212-2, groups of mice were injected (i.p.) twice daily for 5 days with increasing doses of the agonist (1-8 mg·kg -1 ; Moranta et al., 2007) . The first group of mice was killed 1 h after the last dose of WIN55212-2 to assess the brain content of target proteins. The second group of mice was injected with rimonabant (10 mg·kg -1 , i.p.) to precipitate and evaluate the cannabinoid withdrawal syndrome (Moranta et al., 2007) . Finally, the third group of mice was killed 1 h after rimonabant-precipitated withdrawal to quantify various signalling proteins in the brain. The hypothermic response induced by WIN55212-2 (acute, chronic and withdrawal effects) was also assessed (rectal temperature; Moranta et al., 2007) to monitor a wellknown pharmacological effect of CB1 receptor agonists (Ledent et al., 1999) .
Preparation of brain samples and subcellular fractionation
WT, CB1 and CB2 receptor KO mice, as well as CD1 cannabinoid-treated mice were killed without anaesthesia by decapitation at the indicated times. The cerebral cortex, corpus striatum (caudate/putamen and nucleus accumbens), cerebellum and thalamus/hypothalamus, regions enriched in CB1 and/or CB2 receptors (Herkenham et al., 1991; Gong et al., 2006) , were dissected on ice, frozen in liquid nitrogen and stored at -80°C. Brain samples (total homogenate) were prepared for Western blot analysis of proteins as described (García-Fuster et al., 2007a; 2008a,b) .
Additional experiments were carried out to assess at the subcellular level (cerebral cortex) the regulation of FADD and p-Ser191 FADD in WT, CB1 and CB2 receptor KO mice, as well as the modulation of FADD forms and casein kinase (CK) 1a after the acute treatments with WIN55212-2 in CD1 mice. Protein localization was monitored by use of the subcellular proteome extraction kit (ProteoExtract, Calbiochem, Darmstadt, Germany) as described previously (García-Fuster et al., 2007a; 2008a) . This method yields four sub-proteomes enriched in cytosolic (F1), membrane and membrane organelle-localized (F2), soluble and DNA-associated nuclear (F3) and cytoskeletal (F4) proteins. The selectivity of this procedure was assessed by immunodetection of PEA-15 in F1, Fas receptor in F2, nuclear protein prostate apoptosis response 4 (PAR-4) in F3 and neurofilament-L (NF-L) in F4 (see García-Fuster et al., 2008a) .
Functional assay for apoptotic cell death
The potential of genetic deletion of CB receptors and that of WIN55212-2 treatments to induce abnormal brain cell death was monitored by measuring the cleavage of the nuclear enzyme poly(ADP-ribose)-polymerase (PARP-1; Putt et al., 2005) using the PARP cleavage detection kit (Calbiochem). The death substrate PARP-1 (116 kDa) is cleaved into specific 85 and 29 kDa fragments after activation of caspases-3/7 (Kumar, 2007) . The pattern of PARP-1 cleavage in the cerebral cortex of WT, CB 1 and CB2 KO mice, as well as in vehicle-and WIN55-212-2-treated CD1 mice, was assessed by Western blot analysis (García-Fuster et al., 2008b) .
SDS-PAGE, Western blots and quantification of target proteins
Target proteins were quantified by Western blot as described (García-Fuster et al., 2007a; 2008a,b) . Briefly, brain proteins (40 or 60 mg of total homogenate; 15 mg of each subcellular fraction) were resolved by electrophoresis on 10-12% SDS-PAGE minigels, and then electrotransferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA). In some experiments, the transfer buffer also contained 0.1% SDS to better resolve Fas receptor aggregates. After blocking non-specific protein-binding sites, the membranes were incubated overnight at 4°C in blocking solution with the primary antibody (1:500-1:10 000 dilution), and the blots were developed with peroxidase-conjugated secondary antibodies (antirabbit, anti-goat or anti-mouse IgG; 1:5000 dilution for 1 h at 24°C). Blots were subjected to enhanced chemiluminescence (ECL detection system, Amersham, Buckinghamshire, UK), and the signal of bound antibody was visualized by exposure to autoradiographic film (Amersham ECL Hyperfilm). The primary antibodies (immunoaffinity-purified epitopes) used are described in Supporting Information Table S1 .
The autoradiograms were quantified as described (García-Fuster et al., 2007b) . For a direct comparison, samples from CB 1 or CB2 receptor KO mice and the corresponding WT control mice were run together in the same gel to assess for basal differences in CB receptor genotypes. The amount of target proteins in brain samples of CD1 mice treated with cannabinoid drugs was compared in the same gel with that of control mice that received drug vehicle. These experiments were repeated four to eight times in different gels. Percentage changes in immunoreactivity with respect to control samples (100%) were calculated in the various gels, and the mean value was used as a final estimate. As a control for sample loading and protein transfer, the blots were stripped (Boronat et al., 2001) and re-probed with anti-b-actin monoclonal antibody, and target protein content was normalized to that of b-actin. Drug activation of MAPKs and Akt1 are expressed as the ratio of the phosphorylated enzyme (p-ERK, etc.) to the corresponding total enzyme, and reported as a percentage of that in control mice.
Data analyses and statistics
Results are expressed as means Ϯ SEM values. All series of data were analysed with the program GraphPad Prism, version 4.0 (GraphPad Software, Inc., San Diego, CA, USA). Neurochemical differences between WT mice and CB receptor KO mice were assessed by a Student's two-tailed t-test. Drug effects and global cannabinoid withdrawal scores were analysed by oneway ANOVA followed by a Bonferroni post hoc test for multiple comparisons. Pearson's correlation coefficients were calculated to test for possible association between variables. The level of significance chosen was P Յ 0.05.
Materials
WIN55212-2 and JWH133 were purchased from Tocris Cookson Ltd (Avonmouth, UK). Rimonabant (SR141716A) was a gift from Sanofi Recherche (Montpellier, France). Drug and molecular target nomenclature in this report follows Alexander et al. (2009) . WT and CB receptor KO mice: cleavage of the nuclear enzyme PARP In CB1 receptor KO mice, compared to their WT littermate controls, Fas aggregates showed a trend towards a decrease in all three brain regions examined, but this decrease was significant only in the cerebellum (Figure 1 ). Native and glycosylated Fas forms did not differ between receptor genotypes (data not shown). FADD content was reduced more consistently across the brain regions (14-33%) (Figure 1 ). In contrast, p-Ser191 FADD was increased (17-27%) in mutant mice ( Figure 1 ). Thus, genetic deletion of CB1 receptors resulted in a net increase in the p-Ser191 FADD/FADD ratio in all three Figure 1 Effects of constitutive deletion of CB1 receptors (WT, n = 9; CB1 KO, n = 9) on the basal contents of Fas receptor (~116/203 kDa aggregated forms), FADD (~52 kDa dimeric form) and p-Ser191 FADD (~116 kDa oligomeric form) in the mouse cerebral cortex (A), corpus striatum (B) and cerebellum (C). The columns are means Ϯ SEM values (% immunoreactivity) expressed as percentage of WT control mice. *P < 0.05; **P < 0.01 when compared with the corresponding WT group (two-tailed Student's t-test). Right: representative immunoblots for Fas, FADD, p-FADD and b-actin in the various brain regions of WT (n = 4) and CB1 KO (n = 4) mice. Protein molecular masses (kDa) were estimated from referenced standards.
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regions: cerebral cortex (WT: 0.99 Ϯ 0.05; KO: 1.44 Ϯ 0.14; P < 0.01), corpus striatum (WT: 1.00 Ϯ 0.07; KO: 1.42 Ϯ 0.10; P < 0.005) and cerebellum (WT: 1.06 Ϯ 0.11; KO: 2.08 Ϯ 0.42; P < 0.05).
In CB2 receptor KO mice, brain Fas forms were similar to those in WT controls, except for Fas aggregates which were clearly increased in striatum (Figure 2 ). In these mutant mice, FADD was increased in thalamus/hypothalamus and p-Ser191 FADD in cortex and striatum ( Figure 2 ). CB2 receptor deletion did not alter the p-Ser191 FADD/FADD ratio in cortex (WT: 1.02 Ϯ 0.06; KO: 1.12 Ϯ 0.07), striatum (WT: 1.08 Ϯ 0.12; KO: 1.17 Ϯ 0.07) or thalamus/hypothalamus (WT: 0.96 Ϯ 0.04; KO: 0.90 Ϯ 0.06; all P > 0.05).
Consistent with these findings using total homogenates, in key subcellular compartments (cytosol; F1/membranes; F2) of a representative CB1 KO mouse, cortical FADD was reduced (48-67%), and p-Ser191 FADD was augmented (15-157%) ( Figure 3A ). In a CB2 receptor KO mouse, minimal increases of FADD (3-20%) and marked up-regulations of p-Ser191 FADD (21-113%) were measured in the cytosol and membrane fractions ( Figure 3B) .
Notably, PARP-1 cleavage to the 85 kDa main fragment (a marker of apoptosis) in brains of CB1 and CB2 receptor KO mice was not different from that measured in WT animals ( Figure 3C ).
Acute effects of WIN55212-2 and JWH133 on brain FADD and p-Ser191 FADD: interaction of FADD and CK1a
Acute treatments of CD1 mice with WIN55212-2 (0.5, 1 and 8 mg·kg -1 ), compared with vehicle administration, did not alter Fas (native, glycosylated and aggregated forms) in the cerebral cortex (data not shown). WIN55212-2 (0.5 mg·kg -1 ) increased cortical FADD, whereas higher doses (1 and Figure 2 Effects of constitutive deletion of CB2 receptors (WT, n = 12; CB2 KO, n = 13) on the basal contents of Fas receptor (~116/203 kDa aggregated forms), FADD (~52 kDa dimeric form) and p-Ser191 FADD (~116 kDa oligomeric form) in the mouse cerebral cortex (A), corpus striatum (B) and thalamus/hypothalamus (C). The columns are means Ϯ SEM values (% immunoreactivity), expressed as percentage of WT control mice. *P < 0.05; **P < 0.01; ***P < 0.0001 when compared with the corresponding WT group (Student's t-test). Right: representative immunoblots for Fas, FADD, p-FADD and b-actin in the various brain regions of WT (n = 4) and CB2 KO (n = 4) mice. Protein molecular masses (kDa) were estimated from referenced standards.
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-1 ) decreased this protein in cortex ( Figure 4A ). WIN55212-2 also induced bell-shaped dose effects on p-Ser191 FADD, but in the opposite direction, with no changes at the lowest dose and increases at the higher doses ( Figure 4B ). Rimonabant abolished the opposite effects of WIN55212-2 (1 mg·kg -1 ) on FADD and p-Ser191 FADD (Figure 5 ), indicating a CB1 receptor-related mechanism. The CB2 receptor agonist JWH133 (1 and 3 mg·kg -1 ) did not induce significant changes of FADD or p-Ser191 FADD in cortex ( Figure 4C,D) . As expected, WIN55212-2, but not JWH133, induced hypothermia in mice (data not shown).
Notably, WIN55212-2 (0.5-8 mg·kg -1 ) modulated in opposite directions the content of FADD and p-Ser191 FADD in the same cortical samples (r = -0.80) ( Figure 6A ). Thus, the activation of CB1 receptors can decrease (lower dose) or increase (higher doses) the ratio of p-Ser191 FADD/FADD in the mouse brain (vehicle: 1.02 Ϯ 0.05; 0.5 mg·kg -1 WIN: 0.63 Ϯ 0.09, P < 0.001; 1 mg·kg -1 WIN: 1.66 Ϯ 0.18, P < 0.005; 8 mg·kg -1 WIN: 3.66 Ϯ 0.47, P < 0.001). At the subcellular level, WIN55212-2 (1 and 8 mg·kg -1 ) increased p-Ser191 FADD in cytosol (77 and 120%) and membranes (158 and 166%) and to a lesser extent in nucleus (14 and 40%) ( Figure 6B ). In contrast, WIN55212-2 decreased FADD in membranes (20 and 71%) and nucleus (5 and 31%), and increased its content in cytosol (20 and 30%) ( Figure 6C ). WIN55212-2 also increased levels of the kinase CK1a in cytosol (28 and 66%) ( Figure 6D ), which was coincident with the marked enhancement of p-Ser191 FADD in this compartment ( Figure 6C,D) . Figure 6E . (C) Effects of constitutive deletion of CB1 receptor or CB2 receptor on the content of PARP-1 (~116 kDa) and its cleaved fragment (~85 kDa) in the cerebral cortex of WT (n = 6-12) and KO (n = 7-13) mice. The columns are means Ϯ SEM values expressed as percentage of total immunodensity (IOD units) for each group (PARP plus fragment). NC: negative control; whole cell extract of human HL60 leukemia cells. PC: positive control; etoposide-induced apoptosis in HL60 cells. Two-tailed Student's t-tests did not detect significant differences between WT and KO mice for PARP-1 and its cleaved fragment. Bottom: representative immunoblots for the pattern of PARP-1 cleavage in HL60 cells and the cerebral cortex of WT/KO mice (n = 2 for each group). A representative immunoblot for the 29 kDa PARP-1 fragment and b-actin in the cortex of WT (n = 6) and CB1 KO (n = 6) mice is included (negative results). (A-C) Protein molecular masses (kDa) were estimated from referenced standards. -1 , i.p., 1 h, n = 6; SR, 10 mg·kg -1 , i.p., 100 min, n = 5) or in combination 40 min apart (SR + WIN, n = 6). Control mice received drug vehicle (VH, 2 mL·kg -1 , i.p., n = 8). The columns are means Ϯ SEM values of protein immunoreactivity, and expressed as percentage of the corresponding VH-treated group. One-way ANOVA detected significant differences between the groups of treatments for FADD [F(3,21) = 3.10, P = 0.048] and p-FADD [F(3,21) = 7.34, P = 0.0015]. *P < 0.05, **P < 0.01 when compared with the corresponding VH group; †P < 0.05 when compared with the corresponding WIN group (ANOVA followed by Bonferroni's test). Bottom: representative immunoblots for the effects of WIN, SR and SR + WIN on FADD, p-FADD and b-actin in the mouse cerebral cortex. (A and B) . Protein molecular masses (kDa) were estimated from referenced standards.
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decreased FADD and increased p-Ser191 FADD in cortex ( Figure 7A,B) . Chronic agonist treatment was also associated, although to a lesser extent, with down-regulation of FADD and up-regulation of p-Ser191 FADD, which suggested the development of adaptive changes (p-FADD/FADD ratio; vehicle: 1.01 Ϯ 0.05, chronic WIN55212-2: 2.29 Ϯ 0.24, P < 0.005; Figure 7 ). Tolerance to the acute hypothermic effect of WIN55212-2 was also observed after chronic treatment (data not shown). In chronically WIN55212-2-treated mice, rimonabant induced the rapid expression of somatic signs of withdrawal (data not shown), indicating the induction of dependence on this agonist. In WIN55212-2-withdrawn mice, the content of FADD and p-Ser191 FADD returned, partially or completely, to basal values (Figure 7) .
Effects of WIN55212-2 and JWH133 on mitochondrial apoptotic proteins and PARP cleavage
The acute and chronic treatments of CD1 mice with WIN55212-2, as well as rimonabant-precipitated withdrawal, did not alter the contents of cytochrome c, apoptosisinducing factor (AIF) or the cleavage of PARP-1 in the cerebral cortex (Supporting Information Figure S1 ). Similar negative results were obtained after acute treatments with JWH133 (data not shown). 
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Acute, chronic and withdrawal effects of WIN55212-2 on the activation of brain MAPKs and regulation of Akt and PEA-15
Acute treatment of CD1 mice with WIN55212-2 markedly stimulated activation of ERK1/2 (shown as the ratio of pERK1/ 2 : total ERK1/2) in the cerebral cortex, although the activation of this anti-apoptotic kinase was lost after the chronic treatment ( Figure 8A ). The effect of WIN55212-2 on the phosphorylation of pro-apoptotic JNK1/2 and p38 MAPKs showed a similar time-course to that of ERK, with acute activations after acute treatment, followed by loss of effect after chronic treatment ( Figure 8B,C) . In WIN55212-2-withdrawn (rimonabant) mice, activation of JNK1/2 and p38 kinase was increased to levels above those after chronic agonist treatment and above values after vehicle (Figure 8 ). The corresponding ratio for ERK1/2 was unaffected by withdrawal of WIN55212-2.
Activation of Akt1 has been shown to induce the phosphorylation of PEA-15 (p-Ser116) promoting anti-apoptotic actions. Acute WIN55212-2 activated Akt1 (increased p-Akt : total Akt ratio) and markedly increased p-Ser116 PEA-15 in the cerebral cortex ( Figure 9A,B) . However, chronic WIN55212-2 treatment and rimonabant-precipitated withdrawal were not associated with significant changes in Akt1 activation and PEA-15 phosphorylation (Figure 9 ). The acute, chronic and withdrawal effects of WIN55212-2 did not alter the content of total PEA-15 (un-phosphorylated PEA-15 can also regulate the ERK pathway) ( Figure 9B , tPEA-15 immunoblot).
Discussion
Role of CB receptors in the tonic control of apoptotic Fas/FADD complex in the mouse brain
The association of Fas receptor with the cytosolic adaptor FADD is the initial step in the activation of the extrinsic apoptotic pathway (Algeciras-Schimnich et al., 2002) . Notably, the over-expression of FADD results in Fasindependent triggering of apoptosis (Chinnaiyan et al., 1995) , and its phosphorylation (p-Ser191, mouse) is associated with non-apoptotic actions (Alappat et al., 2005) . Therefore, Fas and the multifunctional FADD might participate in the deleterious or beneficial actions of natural and synthetic cannabinoids on neuronal survival (see Introduction).
In this context, WT and CB receptor KO mice were first compared to assess if an endogenous cannabinoid tone regulates the basal expression of Fas and/or FADD in various brain regions (total homogenate and subcellular compartments). In CB 1 receptor KO mice, the contents of Fas aggregates (relevant receptor forms in transmitting the death signal; Algeciras-Schimnich et al., 2002) and total FADD (non-phosphorylated/phosphorylated forms; García-Fuster et al., 2007a) were reduced, which suggested that endocannabinoids acting on CB1 receptors stimulate the expression of Fas/FADD complexes (pro-apoptotic action). CB1 receptordeficient mice also showed an increased brain content of oligomeric p-Ser191 FADD (p-FADD/FADD ratio increased), suggesting that CB1 receptors tonically inhibit the phosphorylation of FADD, which could also favour the induction of pro-apoptotic actions. Consistent with these findings, a low dose (0.5 mg·kg -1 ) of the CB1 receptor agonist WIN55212-2 increased brain FADD and decreased p-Ser191 FADD (p-FADD/FADD ratio decreased; see further discussion below), which was opposite to the changes of FADD in CB1 KO mice. Therefore, CB1 receptors, which exhibit a high level of constitutive activity (Gifford and Ashby, 1996; Leterrier et al., 2004) , appear to exert a tonic activation of the Figure 7 Acute, chronic and withdrawal effects of the CB1 receptor agonist WIN55212-2 on the content of (A) FADD (~52 kDa dimeric form) and (B) p-Ser191 FADD (~116 kDa oligomeric form) in the cerebral cortex of CD1 mice. Groups of mice were treated (i.p.) with drug vehicle (VH, n = 5), acute WIN (WIN, 8 mg·kg -1 , 1 h, n = 5), chronic WIN (CHR, 1-8 mg·kg -1 , increasing doses for 5 days, n = 5) and chronic WIN followed 4 h later by the CB1 receptor antagonist rimonabant (WITH, 10 mg·kg -1 for 1 h, n = 5) and killed at the indicated times. The columns are means Ϯ SEM values of protein immunoreactivity and expressed as percentage of the corresponding VH-treated group. One-way ANOVA detected significant differences between the groups of treatments for FADD [F(3,16) = 27.10, P < 0.0001] and p-FADD [F(3,16) = 18.80, P < 0.0001]. *P < 0.05, **P < 0.001 when compared with the corresponding VH group; †P < 0.001 when compared with the corresponding CHR group (ANOVA followed by Bonferroni's test). Bottom: representative immunoblots for the effects of WIN, CHR and WITH on FADD, p-FADD and b-actin in the mouse cerebral cortex. (A and B) . Protein molecular masses (kDa) were estimated from referenced standards.
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pro-apoptotic Fas/FADD complexes. However, rimonabant (10 mg·kg -1 ), a selective CB1 receptor antagonist/inverse agonist did not alter FADD or p-Ser191 FADD in brains of CD1 mice, suggesting that the postulated receptor tonic control on this system is moderate. On the other hand, CB1 receptor KO mice showed no differences in the brain content of anandamide and 2-arachidonoylglycerol compared with WT mice (Maccarrone et al., 2001) , indicating that the modulation of Fas/FADD complexes observed in CB1 receptor mutant mice was not the net result of an altered endogenous activation of CB2 receptors.
In brain regions of CB2 receptor KO mice, the contents of Fas aggregates and total FADD were normal or showed increases (changes opposite to those in CB1 receptor KO mice), and p-Ser191 FADD/FADD ratio was not modified in any brain region. These results indicate that endocannabinoids acting on CB2 receptors do not appear to tonically regulate the expression of pro-apoptotic Fas/FADD complex. In line with these negative findings, the selective CB2 receptor agonist JWH133 did not alter FADD in the cerebral cortex of CD1 mice. In the striatum of CB2 receptor KO mice, a marked increase in Fas aggregates was quantified, but the adaptor FADD was unaltered. Therefore, the degree of constitutive activity of CB2 receptors regulating the apoptotic Fas/FADD complex, if any, is low (but see Viscomi et al., 2009 ; CB2 agonists and antagonists induced opposite effects on various effectors).
The alterations of Fas/FADD in brains of CB receptor KO mice did not appear to result in an increased cell death. Thus, Figure 8 (A-C) Acute, chronic and withdrawal effects of the CB1 receptor agonist WIN55212-2 on the activation of (A) ERK1/2 (B) JNK1/2 and (C) p38 MAPKs (expressed as the ratio of phosphorylated enzyme to the corresponding total enzyme) in the cerebral cortex of CD1 mice. Groups of mice were treated (i.p.) with drug vehicle (VH, n = 5), acute WIN (WIN, 8 mg·kg -1 , 1 h, n = 5), chronic WIN (CHR, 1-8 mg·kg -1 , increasing doses for 5 days, n = 5) and chronic WIN followed 4 h later by the CB1 receptor antagonist rimonabant (WITH, 10 mg·kg -1 for 1 h, n = 5) and killed at the indicated times. The columns are means Ϯ SEM values of protein immunoreactivity, and expressed as percentage of the corresponding VH-treated group. One-way ANOVA detected significant differences between the groups of treatments for ERK1/2 [F(3,16) = 5.30, P = 0.01], JNK1/2 [F(3,16) = 22.56, P < 0.0001] and p38 kinase [F(3,16) = 4.40, P = 0.02], *P < 0.05, **P < 0.01, ***P < 0.001 when compared with the corresponding VH group; †P < 0.05 when compared with the corresponding CHR group (ANOVA followed by Bonferroni's test). Right: representative immunoblots for the effects of WIN, CHR and WITH on MAPKs in the mouse cerebral cortex. (A-C) Protein molecular masses (kDa) were estimated from referenced standards.
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M Álvaro-Bartolomé et al the pattern of cleavage of the nuclear enzyme PARP-1 (a marker of apoptosis; Putt et al., 2005) in the cerebral cortex of CB1 or CB2 receptor KO mice was not different to that in WT mice, which would discount an abnormal activation of executioner caspases-3/7 (Kumar, 2007) .
Recently, Fas/FADD content was found to be markedly increased in brains of d-opioid receptor KO mice, indicating that this constitutively activated receptor (Costa and Herz, 1989 ) tonically inhibited the pro-apoptotic complex (García-Fuster et al., 2007b) . Given the functional interactions between cannabinoids and opiates, and particularly between CB 1 and d-opioid receptors (Urigüen et al., 2005) , the Fas/ FADD complex could be, in part, under the opposite tonic control of these inhibitory receptors (d-receptor: significant reduction in FADD signalling; CB1 receptor: modest increase in FADD signalling). These mechanisms could be involved in the neuroprotective actions, including the prevention of apoptosis, induced by stimulation of d-opioid receptors (Narita et al., 2006) .
Modulation of FADD and other apoptotic proteins by CB receptors in CD1 mice: role of CB1 receptors in the regulation of non-apoptotic p-Ser191 FADD
Many in vitro and in vivo studies have reported neurotoxic or neuroprotective effects induced by natural and synthetic cannabinoids acting at CB receptors (Downer et al., 2003; Maccarrone and Finazzi-Agró, 2003; Aguado et al., 2007) . Thus, the agonist WIN55212-2 was shown to induce CB1 receptormediated apoptosis in cultured cells (Pozzoli et al., 2006) and CB2 receptor-mediated neuroprotection in mice (Price et al., 2009 ).
In the current study, acute treatment with WIN55212-2 (1 and 8 mg·kg -1 ) reduced FADD and increased p-Ser191 FADD (p-FADD/FADD ratio also increased) in the cerebral cortex of CD1 mice (effects prevented by rimonabant), clearly indicating that CB1 receptor stimulation (with moderate/high agonist doses) not only results in attenuation of apoptotic FADD signalling (possible neuroprotection; García-Fuster et al., 2007a; 2008b) , but also in the activation of p-Ser191 FADD, the protein form associated with non-apoptotic actions (Alappat et al., 2005) including the induction of neuroplasticity Ramos-Miguel et al., 2009; 2010) . In contrast, relevant doses of JWH133, a selective CB2 receptor agonist, did not alter the content of brain FADD or p-Ser191 FADD, suggesting the specific involvement of CB1 receptors in the regulation of the extrinsic apoptotic pathway.
Notably, acute WIN55212-2 (0.5, 1 and 8 mg·kg -1 ) modulated in opposite directions FADD and p-Ser191 FADD in the same cortical samples (total homogenate and subcellular compartments), most probably through the interaction of FADD with CK1a, the relevant phosphorylating kinase (Alappat et al., 2005; García-Fuster et al., 2008a) . Similar inverse relationships for FADD and p-FADD (with increased p-FADD/FADD ratio) were observed for the effects of opiate drugs (García-Fuster et al., 2007a; 2008a) and cocaine in rat brain. These results indicate that different drugs of abuse share the capacity to induce the interconversion between non-phosphorylated FADD and p-FADD, which appears to favour the non-apoptotic (neuroplastic) activities of this multifunctional protein (RamosMiguel et al., 2009; 2010) . As observed with opiate drugs and cocaine (García-Fuster et al., 2007a; , WIN55212-2 also induced bell-shaped dose effects on brain FADD and p-Ser191 FADD, although the inhibition of FADD and the stimulation of p-FADD were more marked. Various biphasic effects induced by endocannabinoids (Sulcova et al., 1998) and synthetic cannabinoids (Rubino et al., 2008) have been reported, Figure 9 (A and B) Acute, chronic and withdrawal effects of the CB1 receptor agonist WIN55212-2 on the activation of (A) Akt-1 (expressed as the ratio of phosphorylated enzyme to total enzyme) and (B) PEA-15 (expressed as the ratio of phosphorylated PEA-15 to total PEA-15) in the cerebral cortex of CD1 mice. Groups of mice were treated (i.p.) with drug vehicle (VH, n = 5), acute WIN (WIN, 8 mg·kg -1 , 1 h, n = 5), chronic WIN (CHR, 1-8 mg·kg -1 , 5 days, n = 5) and chronic WIN followed 4 h later by the CB1 receptor antagonist rimonabant (WITH, 10 mg·kg -1 for 1 h, n = 5) and killed at the indicated times. The columns are means Ϯ SEM values of protein immunoreactivity, and expressed as percentage of the corresponding VH-treated group. One-way ANOVA detected significant differences between the groups of treatments for Akt-1 activation [F(3,16) = 5.88, P = 0.007] and PEA-15 activation [F(3,16) = 8.01, P = 0.0018]. *P < 0.05, **P < 0.01 when compared with the corresponding VH group (ANOVA followed by Bonferroni's test). Bottom: representative immunoblots for Akt-1 and PEA-15 in the mouse cerebral cortex, after WIN, CHR or WITH treatments. (A and B) . Protein molecular masses (kDa) were estimated from referenced standards.
Cannabinoid receptors and Fas/FADD apoptotic complex M Álvaro-Bartolomé et al which could be related to the fact that CB1 receptors are activated under basal conditions (see above; FADD stimulation at a low dose of WIN55212-2, and FADD inhibition at larger agonist doses that would neutralize receptor constitutive activity when drug concentration is greater than that of endogenous ligand; see Barna et al., 2009) .
It is noteworthy that chronic WIN55212-2 administration (5 days) also resulted in down-regulation of FADD and up-regulation of p-Ser191 FADD in the brain, which indicate a sustained attenuation of apoptotic signalling in spite of the induction of some tolerance (tachyphylaxis) upon the repeated stimulation of CB1 receptors (Sim-Selley, 2003) . Rimonabant-precipitated WIN55212-2 withdrawal did not cause a rebound of FADD or p-Ser191 FADD over control values. However, similar acute and chronic treatments of rats with WIN55212-2 did not alter brain FADD (García-Fuster et al., 2007a) , indicating important species differences in total FADD regulation by the CB receptor agonist.
Interestingly, neither acute/chronic WIN55212-2 (and withdrawal effects) nor acute JWH133 altered the brain contents of cytochrome c (a mitochondrial activator of caspase-3; Galluzzi et al., 2009) and AIF (the main mitochondrial mediator of caspase-independent apoptosis and a key cell death effector in neurones; Galluzzi et al., 2009) , suggesting a lack of abnormal activation of the intrinsic apoptotic pathway after the stimulation of CB receptors. In brains of CD1 mice, moreover, the cleavage of PARP-1 (mediated in part by caspases-3/7 and AIF) was not altered by the various WIN55212-2 treatments. In contrast to these in vivo data, D 9 -THC was reported to promote, through the activation of CB1 receptors, apoptotic effects (increased cytochrome c and caspase-3, and DNA fragmentation) in cultured cortical neurones (Downer et al., 2003) . However, treatment of adult rats with D 9 -THC did not result in activation of the mitochondrial apoptotic pathway (Downer et al., 2007) . These results highlight the relevance of in vivo studies in the assessment of programmed cell death regulation by cannabinoids.
Regulation of MAPKs and Akt1/PEA-15 pathways by CB1 receptors in the mouse brain
Numerous intracellular signalling systems are involved in mediating the effects of CB receptors (Demuth and Molleman, 2006) . In particular, the in vivo stimulation of CB1 receptors with D 9 -THC has been shown to induce the phosphorylation (activation) of ERK1/2 (Valjent et al., 2001 ) and PI3K/Akt (Ozaita et al., 2007) in rodent brain regions. Therefore, the activation of these anti-apoptotic cascades could participate in the neuroprotection induced by cannabinoids (see Ozaita et al., 2007) . However, the acute sequential stimulation of Raf-MEK1/2-ERK1/2 induced by WIN55212-2 in the rat cerebral cortex was no longer observed after chronic agonist treatment, indicating that the activation of this neuroprotective system by CB1 receptors is short lasting (Moranta et al., 2007) . Interestingly, the activation of Akt1 stimulates p-Ser116 PEA-15 to promote, together, anti-apoptotic actions (see Ramos-Miguel et al., 2009) .
In the present study, acute, but not chronic, treatment with WIN55212-2 markedly stimulated the activation of antiapoptotic ERK1/2 and Akt1/p-Ser 116 PEA-15, as well as proapoptotic JNK1/2 and p38 MAPK in the mouse cerebral cortex. This suggests that the acute in vivo neuroprotection induced by some cannabinoids (see above) could be the result of a favourable balance between the relative activation of anti-and pro-apoptotic signalling pathways. In contrast to FADD and p-Ser191 FADD, the lack of a sustained stimulation of anti-and pro-apoptotic cascades upon chronic WIN55212-2 treatment probably reflects the rapid induction of CB 1 receptor desensitization (Sim-Selley, 2003) in the regulation of these systems. Also at variance with FADD, rimonabant-precipitated withdrawal after chronic WIN55212-2 was associated with significant rebounds in the phosphorylation of JNK1/2 and p38 MAPK, but not of ERK1/2 and Akt1/PEA15, demonstrating the rapid activation of proapoptotic cascades (without apparent functional repercussion; see above) during the expression of the cannabinoid withdrawal syndrome in mice. This reactivation of JNK1/2 and p38 MAPK could be related to the increase in the content/ release of anandamide observed in brains of cannabinoidwithdrawn rats (González et al., 2004) , these pro-apoptotic cascades being more sensitive to the endogenous agonist.
The present in vivo study indicates that the acute and chronic stimulation of CB 1 receptors is associated with a marked down-regulation of brain FADD, a major proapoptotic molecule of the extrinsic cell death pathway. This may represent a relevant molecular mechanism to explain, in part, the neuroprotective effects induced by natural and synthetic cannabinoids (Guzmán et al., 2002) . In addition, the acute and chronic stimulation of CB1 receptors was also associated with up-regulation of p-Ser191 FADD, the protein form that mediates non-apoptotic actions including brain plasticity (Ramos-Miguel et al., 2009; 2010) . The link between CB1 receptors and the multifunctional protein FADD provides new insights into the complex neurobiology of the cannabinoid system.
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Additional Supporting Information may be found in the online version of this article. Figure S1 Acute effects of the CB1 receptor agonist WIN55212-2 on the contents of (A) cytochrome c and (B) AIF in the cerebral cortex of CD1 mice. Groups of mice were treated (i.p.) with drug vehicle (VH, n = 12) or WIN (0.5, 1 and 8 mg·kg -1 , 1 h, n = 5 for each group). The columns are means Ϯ SEM values of protein immunoreactivity and expressed as percentage of the corresponding VH-treated group. One-way ANOVA did not detect significant differences between the groups of treatments for cytochrome c [F(3,23) = 3.00, P = 0.054] or AIF [F(3,23) = 0.77, P = 0.523]. Bottom: representative immunoblots for the effects of WIN on cytochrome c, AIF and b-actin in the mouse cerebral cortex. Similarly, chronic WIN55212-2 treatment (1-8 mg·kg -1 , 5 days) was not associated with significant changes in cytochrome c or AIF (data not shown) (C) Effects of vehicle (VH, n = 5), acute WIN55212-2 (WIN, n = 5), chronic WIN (CHR, n = 5) and chronic WIN followed by withdrawal (WITH, n = 5) on the content of PARP-1 and its cleaved fragment in the cerebral cortex of CD1 mice. One-way ANOVA did not detect significant differences between the groups of treatments for PARP-1 [F(3,16) = 2.2, P = 0.12] and its fragment [F(3,16) = 2.37, P = 0.11]. Bottom: representative immunoblot for the effects of VH, WIN, CHR and WITH on the pattern of PARP-1 cleavage in the mouse cerebral cortex (n = 2 for each group of treatment). (A-C) Protein molecular masses (kDa) were estimated from referenced standards. Table S1 Antibodies used for the detection and quantification of apoptotic proteins and other signalling molecules in the mouse brain.
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